Al Arishi H, Frayha H H, Kalloghlian A, Al Alaiyan S
Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Am J Perinatol. 1998;15(11):643-8. doi: 10.1055/s-2007-994083.
Liposomal amphotericin B (L-Amp B), a novel formulation of amphotericin B, is effective for the treatment of invasive fungal infections in children and adults and is associated with less toxicity than the conventional preparation. Data on the use of Liposomal amphotericin B in neonates is scarce. We describe the clinical course of two premature infants who were treated with Liposomal amphotericin B (one infant had candidemia, and the other had candidemia and meningitis), and provide a summary of previously published experience on this topic. Liposomal amphotericin B may be an option for therapy of invasive candidiasis in neonates who are at high risk of nephrotoxicity and other amphotericin-related reactions, but clinical trials are necessary to document its safety and efficacy in this age group.
两性霉素B脂质体（L-Amp B）是两性霉素B的一种新型制剂，对治疗儿童和成人侵袭性真菌感染有效，且与传统制剂相比毒性较小。关于两性霉素B脂质体在新生儿中的使用数据很少。我们描述了两名接受两性霉素B脂质体治疗的早产儿的临床过程（一名婴儿患有念珠菌血症，另一名患有念珠菌血症和脑膜炎），并总结了此前发表的关于该主题的经验。对于有肾毒性和其他两性霉素相关反应高风险的新生儿，两性霉素B脂质体可能是治疗侵袭性念珠菌病的一种选择，但需要进行临床试验来证明其在该年龄组中的安全性和有效性。
